Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)

Marilyn K. Glassberg, Steven D. Nathan, Chin Yu Lin, Elizabeth A. Morgenthien, John L. Stauffer, Willis Chou, Paul W. Noble

Research output: Contribution to journalComment/debate

Abstract

In the Original Publication the colors of Figure 2 have been switched. The correct figures are given below.

Original languageEnglish (US)
Pages (from-to)2927-2929
Number of pages3
JournalAdvances in Therapy
Volume36
Issue number10
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (Advances in Therapy, (2019), 36, 10, (2910-2926), 10.1007/s12325-019-01052-y)'. Together they form a unique fingerprint.

  • Cite this